Canaccord: Aphria Estimated To Post 16% Increase In Recreational Sales In Q1 2021

This morning, Canaccord Genuity’s analyst Matt Bottomley released the firms fiscal first-quarter forecasts for Aphria Inc (TSX: APHA) (NASDAQ: APHA). They also reiterated their C$10 12-month price target and a speculative buy recommendation.

Bottomley’s headlines the note with “Expecting healthy Cdn recreational revenue growth and improved profitability.” Bottomley expects the same robust growth that Aphria reported in the previous quarter. Last quarter Aphria posted a ~27% quarter over quarter increase in their Canadian recreational sales. Bottomley believes that with two times the amount of stores opened and operating in Ontario, which Aphria has a #1 market share, it will be the primary driver in top-line success.

Bottomley further believes that recreational sales in this fiscal quarter will, “represent the company’s largest growth driver for the quarter after several notable market share gains in the prior period.” He forecasts a 20-25% increase in total consumption for Canadian recreational sales, and estimates that Aphria will achieve 16% quarter over quarter growth, which means Aphria’s gross recreational revenue is pegged at an estimated C$65.9 million.

Onto Aphria’s medical arm of the company, Bottomley’s says that fewer patients are booking appointments to renew prescriptions because of COVID-19. He expects medical revenue to be flat quarter over quarter and forecast C$8.6 million as the medical segment’s revenue.

Bottomley expects Aphria’s international revenue to drop by 2% this quarter, down to C$97.1 million as a result of seasonality.

Onto net revenues and gross margin, Bottomley estimates Aphria to have C$159 million in total net revenues, or up a modest 4.5% quarter over quarter. He says, “With some reliance on third-party purchased inputs in the prior period, we estimate that Aphria will see a modest ~50bp improvement in its consolidated adj. gross margin to 26.8% in FQ1/21, or ~C$42.6M.”

Lastly, Bottomley expects adjusted EBITDA to be healthy and come in at C$12.8 million, which is almost a 50% increase quarter over quarter. He believes that this is the case because of anticipated margins being higher and better OpEx spending.

Bottomley ends the note by saying, “the company should remain one of the only profitable LPs among market share leaders at this time.”

Aphria is scheduled to release first quarter financial results on October 15, 2020.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Can the World Actually Supply $6 Copper? | Greg Ferron – PTX Metals

1911 Gold: The Power Of A Mine Restart

Is Gold Repeating the 2005 Setup Before The Big Run? | Geordie Mark

Recommended

Goliath Resources Sees 13% Grade Boost As Stifel Draws Parallels To Great Bear

First Majestic Q4 2025: Record Revenue, Earnings, Annual Silver Output

Related News

Tilray: Canaccord Reiterates US$12 Price Target After Distillery Purchase

On December 8th, Tilray (TSX: TLRY) announced the acquisition of Breckenridge Distillery, a whiskey and...

Friday, December 10, 2021, 03:39:00 PM

Columbia Care: Canaccord Reiterates Price Target Following Project Cannabis Acquisition Announcement

Last Tuesday, Columbia Care (CSE: CCHW) announced that they had signed a definitive agreement to...

Sunday, September 13, 2020, 11:17:00 AM

Canaccord Resumes Coverage On The Valens Company, Issues $6.50 Price Target

This morning Canaccord Genuity resumed coverage on The Valens Company (TSX: VLNS) with a C$6.50...

Monday, July 6, 2020, 10:57:25 AM

Coinbase: Canaccord Drops Price Target From $342 to $275

On February 24th, Coinbase Global, Inc. (NASDAQ: COIN) reported its fourth quarter financial results. The...

Tuesday, March 1, 2022, 04:56:00 PM

Medipharm Labs Receives Price Target Reduction From Canaccord To $1.75

Yesterday, On November 16th, Medipharm Labs (TSX: LABS) reported their third quarter financial results. Reported...

Tuesday, November 17, 2020, 03:37:00 PM